Musashi1 Enhances Cell Growth and Increases Chemoresistance in Neuroblastoma

BACKGROUND/AIM: Neuroblastoma remains a major cause of pediatric cancer mortality and although intensive multimodal treatment strategies have improved survival, they have also led to an increased risk of long-term treatment-related toxicities among survivors. This study aimed to evaluate the potential involvement of (Musashi) Msi1 in neuroblastoma oncogenesis and etoposide treatment response. MATERIALS AND METHODS: The expression of Msi1, an RNA-binding protein and stem cell marker, was examined in MYCN amplified and non-amplified cells, which were then quantified by densitometry. Immunoblotting was used to assess total protein levels in all cell lines. In addition, the impact of Msi1 silencing on etoposide sensitivity was also assessed. RESULTS: silencing of Msi1 was associated with decreased cell proliferation and colony formation, as well as increased sensitivity to etoposide treatment. These changes correlated with altered expression of several cell cycle, proliferation, and DNA damage repair genes that are known Msi1 targets in other malignancies. CONCLUSION: These findings indicate that Msi1 could serve as a novel therapeutic target for high-risk, treatment-refractory neuroblastoma.